OFLOCET
200 MG · comprime pellicule secable · box 10 tablets pellicule
OFLOXACINEReference dated : 2017-12-18. Confirm price and availability with a pharmacist.
Public price
109,60 MAD
What is this medicine?
French reference leaflet: OFLOXACINE BIOGARAN 200 mg, comprimé pelliculé sécable. Confirm indications in Morocco with a pharmacist.
Pharmacotherapeutic class: Fluoroquinolones - ATC code: J01MA01. OFLOXACINE BIOGARAN is an antibiotic from the quinolone family, from the fluoroquinolone group. The active substance is ofloxacine. It acts by killing the bacteria responsible for infections. It is active only against certain strains of bacteria. OFLOXACINE BIOGARAN is indicated for the treatment of the following bacterial infections: · certain urinary tract infections (bladder and kidney infections); · certain genital tract infections in men and women (for example: gonorrhea, a sexually transmitted disease); · certain bone and joint infections; · certain respiratory tract infections; · certain sinus infections; · certain skin infections; · in case of exposure to anthrax. (See section 2 "What is the information you need to know before taking OFLOXACINE BIOGARAN 200 mg, film-coated scored tablet?").
Full clinical reference
Additional sections are available in French. Read the original document; the information concerns the French reference product.
Pregnancy and breastfeeding
Pregnancy
Based on limited data in humans, the use of fluoroquinolones during the first trimester of pregnancy has not been associated with an increased risk of major malformations or other adverse effects on pregnancy outcomes. Animal studies have shown lesions of the articular cartilage in immature animals, but no teratogenic effect. Therefore, ofloxacin is contraindicated during pregnancy (see section 4.3).
Joint damage has been described in children treated with quinolones, but to date, no cases of arthropathy secondary to in utero exposure have been reported.
Breastfeeding
Ofloxacin is excreted in breast milk in small amounts. Because of the risk of arthropathy and other serious toxicities in the breastfed infant, breastfeeding must be discontinued during treatment with ofloxacin (see section 4.3).
Driving
Reactions (for example dizziness/vertigo, drowsiness, visual disturbances) may impair the patient's ability to concentrate and react, and therefore constitute a risk in situations where these abilities are of particular importance (for example driving a vehicle or using a machine).
Adverse effects
The information below is based on data from clinical trials and on long-term experience acquired after marketing.
| Organ system class | Common (≥ 1/100 to < 1/10) | Uncommon (≥ 1/1000 to < 1/100) | Rare (≥ 1/10 000 to < 1/1000) | Very rare (< 1/10 000) | Frequency unknown (cannot be estimated from the available data) |
| Infections and infestations | Fungal infections, Bacterial resistance | ||||
| Hematological and lymphatic system disorders | Anemia, Hemolytic anemia, Leucopenia, Eosinophilia, Thrombocytopenia | Agranulocytosis, Bone marrow failure | |||
| Immune system disorders | Anaphylactic reaction*, Anaphylactoid reaction*, Angioedema* | Anaphylactic shock*, Anaphylactoid shock* | |||
| Metabolism and nutrition disorders | Anorexia, Hypoglycemic coma (see section 4.4). | Hypoglycemia in diabetic patients treated with hypoglycemics*, Hyperglycemia | |||
| Psychiatric disorders 1 | Agitation, Sleep disorders, Insomnia | Psychotic disorders (for example hallucination), Anxiety, Confusional state, Nightmares, Depression, Delirium, Memory disorders. | Psychotic disorders and depression putting the patient at risk, notably suicidal ideation or suicide attempts (see section 4.4), Nervousness | ||
| Nervous system disorders 1 | Dizziness, Headache | Somnolence, Paresthesias, Dysgeusia, Parosmia | Peripheral sensory neuropathy*, Peripheral sensorimotor neuropathy*, Convulsions, Extrapyramidal symptoms or other muscle coordination disorders | Tremor, Dyskinesia, Ageusia, Syncope, Benign intracranial hypertension (pseudotumor cerebri) | |
| Eye disorders 1 | Eye irritation | Visual disorders | Uveitis | ||
| Ear and labyrinth disorders 1 | Vertigo | Tinnitus, Hearing loss | Hearing difficulties | ||
| Cardiac disorders** | Tachycardia | Ventricular arrhythmias, Torsades de pointes (events observed mostly in patients presenting risk factors for QT interval prolongation), ECG-confirmed QT interval prolongation (see sections 4.4 and 4.9). | |||
| Vascular disorders** | Hypotension | ||||
| Respiratory, thoracic and mediastinal disorders | Cough, Nasopharyngitis | Dyspnea, Bronchospasm | Allergic pneumonia, Severe dyspnea | ||
| Gastrointestinal disorders | Abdominal pain, Diarrhea, Nausea, Vomiting | Enterocolitis, sometimes hemorrhagic | Pseudomembranous colitis* | Dyspepsia, Flatulence, Constipation, Pancreatitis | |
| Hepatobiliary disorders | Elevation of liver enzymes (ALAT, ASAT, LDH, gamma-GT and/or alkaline phosphatases), Increase in blood bilirubin | Cholestatic jaundice | Hepatitis which can be severe. Cases of serious liver injury, notably cases of acute liver failure, sometimes fatal, have been reported with ofloxacin, mainly in patients suffering from underlying liver conditions.* | ||
| Skin and subcutaneous tissue disorders | Pruritus, Rash | Urticaria, Hot flashes, Hyperhidrosis, Pustular eruption | Erythema multiforme, Toxic epidermal necrolysis, Photosensitization reaction*, Drug eruption, Vascular purpura, Vasculitis, which can exceptionally lead to skin necrosis | Stevens-Johnson syndrome, Acute generalized exanthematous pustulosis, Drug eruption, Lyell syndrome, Stomatitis, Exfoliative dermatitis | |
| Musculoskeletal and systemic disorders 1 and bone disorders | Tendinitis | Arthralgia, Myalgia, Tendon rupture (for example, Achilles tendon) which can occur within 48 hours after the start of treatment and can be bilateral | Rhabdomyolysis and/or myopathy, Muscle weakness, Muscle tear, Muscle rupture, Ligament rupture, Arthritis, Possible worsening of myasthenia* | ||
| Renal and urinary tract disorders | Increase in serum creatinine | Acute renal failure | Acute interstitial nephritis | ||
| Congenital, familial and genetic disorders | Porphyria attacks in patients with porphyria | ||||
| General disorders and administration site conditions 1 | Fatigue, Fever, Pain (including back, chest and extremity pain) |
* see section 4.4.
** Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ruptures), and regurgitation/insufficiency of one of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).
1 Very rare cases of serious, persistent (lasting several months or years), disabling and potentially irreversible adverse effects, affecting various sensory organ systems, sometimes multiple (notably effects of the type tendinitis, tendon rupture, arthralgia, extremity pain, gait disorders, neuropathies associated with paresthesia and neuralgia, fatigue, psychiatric disorders (including sleep disorders, anxiety, panic attacks, depression, suicidal ideation), memory and concentration disorders and hearing, vision, taste and smell disorders), have been reported in association with the use of quinolones and fluoroquinolones, sometimes independently of pre-existing risk factors (see section 4.4).
Pediatric population
In children: arthropathies (see section 4.4).
Reporting of suspected adverse effects
Reporting of suspected adverse effects after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals report any suspected adverse effect via the national reporting system: French National Agency for Medicines and Health Products Safety (ANSM) and the network of Regional Pharmacovigilance Centres ‑ Website: https://signalement.social-sante.gouv.fr/
Hospital price
68,30 MAD
Type
Originator
References and update dates
CNOPS Referentiel des medicaments · 2017-12-18
Product and price referenceBase de données publique des médicaments (France) · 2026-09-29 · Licence Ouverte
Read medical referenceThis information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.
Price history
Reference price recorded since 2017-12-18: 109,60 MAD
Referenced presentations and strengths
OFLOCET
200 MG · solution for infusion · 1 bottle 40 ml
285,00 MAD
OFLOCET
200 MG · solution for infusion · 1 bottle 40 ml
285,00 MAD
OFLOCET
1.5 MG · solution auriculaire · 20 recipient .5 ml
70,60 MAD
OFLOCET
1.5 MG · solution auriculaire · 20 recipient .5 ml
70,60 MAD
OFLOCET
200 MG · comprime pellicule secable · box 10 tablets pellicule
109,60 MAD
OFLOCET
1,5 MG / 0,5 ML · solution auriculaire · box of 20 recipients unidose
66,00 MAD
OFLOCET
200 MG · film-coated tablet · box of 10
102,40 MAD
OFLOCET
200 MG / 40 ML · solution for injection · box of 1 bottle de 40ml
266,00 MAD
OFLOCET /
1.5 MG / 0.5 ML · solution auriculaire en récipient unidose · box of 20
66,00 MAD
Other strengths and forms
Routes and instructions may differ.
- EXOCINE · 0.3 % · eye drops · 1 bottle 5 ml
- EXOCINE · 0,003 · eye drops · bottle de 5 ml
- EXOCINE 0.3 % · 0.3 % · eye drops · bottle de 5 ml
- FLOXEDOL · 3 MG · eye drops · 1 bottle 5 ml
- FLOXEDOL · 3 MG · eye drops · 1 bottle 5 ml
- FLOXEDOL · 3 MG / ML · eye drops · bottle de 5 ml
- FLOXIMAT · 200 MG · comprime enrobe · box 10 tablets enrobe
- FLOXIMAT · 200 MG · comprime enrobe · box 20 tablets enrobe
- FLOXIMAT · 200 MG · comprime enrobe · box 20 tablets enrobe
- FLOXIMAT · 200 MG · comprime enrobe · box of 10
- FLOXIMAT · 200 MG · comprime enrobe · box of 20
- FLOXIMAT · 200 MG · comprimé enrobé · box of 10